Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.51 USD

73.51
8,106,663

+0.21 (0.29%)

Updated Jul 18, 2024 04:00 PM ET

After-Market: $73.37 -0.14 (-0.19%) 6:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ligand (LGND) Beats on Q1 Earnings & Sales, Raises View

Ligand (LGND) reports higher-than-expected first-quarter 2020 earnings and revenues.

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

Neena Mishra headshot

Biotech ETFs Poised to Benefit From Coronavirus

Rising investor interest in coronavirus related stocks will benefit these ETFs

GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

GILD vs. ILMN: Which Stock Is the Better Value Option?

Is Gilead Sciences, Inc. (GILD) Stock Outpacing Its Medical Peers This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?

5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up

As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.

Sanghamitra Saha headshot

3 Sector ETFs Gaining Momentum in May

After a wobbly start, Wall Street steadied in May. These sector ETFs contributed the most in Wall Street recovery on Monday.

Sanghamitra Saha headshot

Top ETF Stories of April Likely to Hit Headlines Again in May

Energy, gold, online retail and biotech were the most-discussed ETF areas in April and could continue to be so in May.

Remdesivir Gets Emergency Approval: What's In Store for Gilead?

In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?

Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus

Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.

Sanghamitra Saha headshot

ETF Strategies to Follow With U.S. Economy Slowly Reopening

As the U.S. economy is gradually reopening, these investment areas should perform well.

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna

The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa

The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa

Sanghamitra Saha headshot

ETF Asset Report of Coronavirus-Inflicted April

These ETF areas have gained or lost assets in the month of April.

Sanghamitra Saha headshot

5 Top-Performing ETF Areas of April That Are Up At Least 25%

These ETF areas showered gains in the lockdown-infected April.

Mark Vickery headshot

Amazon Misses on Earnings, Apple Beats but Trades Lower

Amazon came in well below earnings estimates, Apple beats on both top & bottom, plus results from Gilead, Amgen and Visa.

Gilead Sciences (GILD) Q1 Earnings and Revenues Beat Estimates

Gilead (GILD) delivered earnings and revenue surprises of 6.33% and 2.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Sweta Jaiswal, FRM headshot

Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir

As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.

The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

Stock Market News for Apr 30, 2020

U.S. stocks closed sharply higher on Wednesday following positive clinical trial data of a drug for potential coronavirus treatment.

Ritujay Ghosh headshot

Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat

A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.

Sanghamitra Saha headshot

5 Small-Cap ETFs Beating S&P 500 in April

Extension of the paycheck protection program, some forgivable loans, strong dollar and the talks of reopening of the economy supported the small-cap ETFs in April.

Sanghamitra Saha headshot

Leveraged Small-Cap and Inverse Leveraged Gold Miners: 2 ETFs to Watch on Outsized Volume

URTY and JDST have seen elevated trading volume on Wednesday.

Should You Buy Gilead Sciences (GILD) Ahead of Earnings?

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Gilead's Coronavirus Drug Shows Positive Data

Gilead's Coronavirus Drug Shows Positive Data